Cidara Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Cidara Therapeutics, Inc. scores 9/10 on the AskCyborg Cyborg Score (Exceptional). Clinical-stage antiviral platform company acquired for $9.2B by Merck based on CD388's breakthrough potential in influenza prevention. Cidara achieved the highest biotech validation—a major pharma acquisition at significant premium based on clinical potential. CD388's Breakthrough Therapy designation and Phase 2b efficacy data demonstrate strong proof-of-concept. The Cloudbreak platform enables.
What is Cidara Therapeutics, Inc.'s industry? Cidara Therapeutics, Inc. (cidara.com) operates in Infectious Disease Drugs. AskCyborg classifies Cidara Therapeutics, Inc. under Infectious Disease Drugs in its company registry.
Cidara Therapeutics operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel ...
Cyborg Score thesis
Clinical-stage antiviral platform company acquired for $9.2B by Merck based on CD388's breakthrough potential in influenza...
Read the full analyst-debate transcript →Get the Latest Cidara Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCidara Therapeutics, Inc. Overview
Pro stress-test →Cidara Therapeutics operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis. Most significantly, Merck agreed to acquire Cidara for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion following FDA Breakthrough Therapy designation.
Strategic Profile
Pro stress-test →The company's proprietary Cloudbreak platform enables development of novel drug-Fc conjugates, with CD388, a long-acting antiviral for influenza prevention, earning Breakthrough Therapy designation from the FDA in October 2025. CD388 demonstrated up to 76.1% prevention efficacy in Phase 2b trials. The $9.2 billion acquisition by Merck validates the platform's potential as a game-changing antiviral technology with applications beyond influenza.
Competitive Landscape
Pro stress-test →CD388 is a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza. The antiviral space includes competitors like Tamiflu (oseltamivir), but CD388's long-acting, strain-agnostic mechanism represents a potentially differentiated approach. The Cloudbreak platform's broader drug-Fc conjugate technology may also enable oncology and infectious disease applications, competing with traditional biopharmaceutical development approaches.
Industry Context
Cidara Therapeutics, Inc. operates in Infectious Disease Drugs.
Key facts
Founded: 2012 · Headquarters: San Diego, California, US · Employees: ~70 (August 2024) · Revenue: ~$0 (pre-revenue clinical-stage company as of Q2 2025) · Market cap: ~$9.2B (acquisition value, November 2025)